Skip to main content

Advanced Search

Haematologica
  • Home
  • Current Issue
  • Ahead Of Print
  • Archive
  • Submit a Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Submit a Manuscript
    • Track a Manuscript
  • About Us
    • About Haematologica
    • Editorial Board
    • Our Policies
  • More
    • Advertising
    • Rights & Permissions
    • Alerts
    • Feedback
    • Contact
D-dimer measured at first venous thromboembolism is associated with future risk of cancer
Olga V. Gran, Sigrid K. Brækkan, Benedikte Paulsen, Hanne Skille, John-Bjarne Hansen
Haematologica December 2016 101: e473-e475; doi:10.3324/haematol.2016.151712
Olga V. Gran
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: olga.gran@uit.no
Sigrid K. Brækkan
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedikte Paulsen
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanne Skille
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John-Bjarne Hansen
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Olga V. Gran1⇑,
  2. Sigrid K. Brækkan1,2,
  3. Benedikte Paulsen1,
  4. Hanne Skille1 and
  5. John-Bjarne Hansen1,2
  1. 1K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway
  2. 2Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
  1. Correspondence: olga.gran{at}uit.no
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
Key words

Over a century has passed since a link between venous thromboembolism (VTE) and cancer was first established.1 Since then, several studies have confirmed the two-way relationship between cancer and VTE.2–4 The risk of cancer is highest in the first year following a VTE event, but persists for several years thereafter.3,5 Coagulation, tumor development and progression are closely related.2,6 Cancer cells interact with the hemostatic system, and tumor cells possess strong procoagulant properties that can induce local activation of the coagulation system.7

D-dimer is a fibrin degradation product, which results from the degradation of cross-linked fibrin by plasmin-induced fibrinolytic activity. Along with clinical parameters, D-dimer is a routine diagnostic tool in the initial assessment of suspected VTE, where low clinical probability and normal D-dimer levels are used to exclude VTE.8 D-dimer levels can be elevated in malignancy, pregnancy, trauma, inflammation, heart disease or following surgery, thus making it a sensitive, yet non-specific marker of coagulation activation. Although increased D-dimer levels are independently associated with VTE and malignancy,9 the link between markedly elevated D-dimer and the risk of subsequent cancer in patients with a first lifetime VTE has scarcely been investigated. Therefore, in a cohort of VTE patients recruited from the general population, we aimed to investigate the association between plasma D-dimer levels measured at incident VTE diagnosis and the risk of cancer within the subsequent two years.

All symptomatic VTE events (n=822) among participants of the Tromsø 1–6 surveys (source population: n=33 885) were included and followed up in the period from January 1, 1994 to December 31, 2012. A detailed description of the Tromsø study cohort has been published previously.10 The VTE events were identified by examining the discharge registry, the autopsy registry and the radiology procedure registry at the University Hospital of North Norway, and thoroughly validated by a review of the medical records, as previously described.11 Subjects with previous or active cancer (n=231), subjects hospitalized at the time of VTE (n=89) and subjects with missing D-dimer values (n=80) were excluded from the analysis. The study population ultimately counted 422 subjects with a first lifetime VTE event. D-dimer levels were measured as part of the diagnostic assessment of patients with suspected VTE, and a positive test was defined as a D-dimer value of >500 ng/ml fibrinogen equivalent units (FEU). All blood samples were analyzed at the Department of Clinical Chemistry at the University Hospital of North Norway, using the NycoCard D-Dimer (Nycomed Pharma, Oslo, Norway) assay from 1994–1998, and the STA®-Liatest® D-Di FM from Stago (Diagnostica Stago, Ansieres, France) from 1998–2012. Information regarding cancer diagnosis date, location and stage was obtained by linkage to the Cancer Registry of Norway.

Statistical analysis was carried out using STATA version 14.0 (Stata Corporation, College Station, TX, USA). Subjects were followed from the date of their first VTE until cancer diagnosis, death, migration, or two years after inclusion, whichever occurred first. D-dimer was analyzed as a categorical variable by dividing the study population into tertiles based on the distribution of D-dimer at the time of the VTE event (tertile 1: <2000 ng/ml, tertile 2: 2000–5000 ng/ml, tertile 3: >5000 ng/ml). Incidence rates (IRs) of cancer were calculated across the tertiles of D-dimer and expressed per 1000 person-years at risk. Cox proportional hazard regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for cancer within one and two years across the tertiles of D-dimer, using tertile 1 as the reference group. Mortality rates per 1000 person-years at one and two years following the VTE event were calculated across the D-dimer tertiles. One subject was diagnosed with cancer on the same day as the VTE event, and was included in the analysis with one day of follow-up. The Fine–Gray model was applied for sensitivity analysis to account for mortality as a competing event.12 Competing risk regression is most often used when the occurrence of one event may alter the chance of another event occurring. Following a VTE, patients are at an increased risk of mortality, especially within the first year after diagnosis.13 Thus, death could prevent an eventual cancer diagnosis. Traditional approaches (Cox proportional hazard regression and Kaplan-Meier) may overestimate the risk of disease, especially when considerable early mortality is present.14

Of the 422 first lifetime VTE events, 239 were DVTs and 183 PEs. During a median follow-up of 4.7 years, 59 cancers were diagnosed. There were 28 cancer diagnoses within one year following a VTE diagnosis, and 34 within two years. Baseline characteristics across the tertiles of D-dimer are presented in Table 1. Subjects in the highest tertile of D-dimer were generally slightly older, less obese, and had a PE more frequently. D-dimer levels were higher in patients who developed cancer than those who did not. The curves of incidence rates of cancer separated early after the VTE diagnosis, and the two year cumulative incidence of cancer was 4.3% in tertile 1 of D-dimer, 6.9% in tertile 2 and 15.5% in tertile 3 (Figure 1). Incidence rates and hazard ratios for developing cancer within one and two years following a VTE by the tertiles of D-dimer are shown in Table 2. The one year risk of cancer was 1.6-fold (95% CI 0.5–5.0) higher in subjects in tertile 2, and 3.3-fold (95% CI 1.2–9.1) higher in subjects in tertile 3, when compared to the lowest D-dimer tertile. The risk persisted when extending the follow-up period to two years in both tertile 2 (HR 1.6, 95% CI 0.6–4.5) and tertile 3 (HR 3.3, 95% CI 1.3–8.4). In patients who developed cancer within one year, the most common cancer sites were those of the lung (29%) and prostate (21%), and hematological cancers were (14%). The most common cancer sites diagnosed within two years of the incident VTE were the lung (27%), prostate (24%) and colorectal (15%) as well as hematological cancers (12%). Subjects in the highest D-dimer tertile who developed cancer within one year, typically had a more advanced cancer at the time of diagnosis. At the time of cancer diagnosis, 80% (8/10) of subjects in tertile 3 and 20% (1/5) in tertile 1 had some degree of metastasis (regional or distant). One and two year mortality rates were higher among subjects who had higher D-dimer levels at VTE diagnosis, in all study participants as well as in those who developed a subsequent cancer (Table 2). The risk (HR) of death during the first year after VTE with subsequent cancer development increased across the tertiles of plasma D-dimer, from 1.9-fold (95% CI 0.6–6.4) in tertile 2 to 5.7-fold (95% CI 2.0–16.5) in tertile 3 compared to tertile 1. The mortality rates (per 1000 person-years) in subjects who developed cancer were higher in tertile 3 (645, 95% CI 308–1351) than in tertile 1 (242, 95% CI 34–1721) or tertile 2 (153, 95% CI 22–1088). In patients who developed cancer within one year, the median time to death was 1020 days in tertile 1, 470 days in tertile 2 and 206 days in tertile 3. When taking the competing risk of death into account, the risk estimates for cancer remained essentially similar (Table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Characteristics at incident VTE according to tertiles of D-dimer.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cumulative incidence of cancer within two years following incident venous thromboembolism (VTE) by tertiles of D-dimer at incident VTE.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Incidence rates (IR), hazard ratios (HR) and competing risk by death (SHR) for cancer and mortality rates (MTR) at one and two years following an incident venous thromboembolism (VTE) according to tertiles of D-dimer.

Previous studies have reported a 2- to 4-fold higher risk of cancer within the first year after a VTE compared to the general population, and that the risk remained about 30% higher for several years following the event.3–5 The relationship between D-dimer and occult cancer in VTE patients has not been extensively studied. Schutgens and colleagues found that high D-dimer levels at diagnosis, or during the first days of treatment for deep vein thrombosis (DVT), were associated with an increased probability of occult cancer.15 In a retrospective study, Han and colleagues16 investigated the role of D-dimer for the prediction of occult cancer in 169 patients with unprovoked VTE, of which 24 developed a subsequent cancer during a median of 5.3 years of follow-up. They found that D-dimer >4000 mg/ml was associated with occult cancer (HR 4.12, 95% CI 1.54–11.04). Even though the study was performed in a Korean population with a non-Western cancer site distribution, and had a strikingly low age at VTE and cancer diagnosis, the risk estimates for cancer were comparable to those in our study.

Fibrin formation is necessary for tumor growth, spread and tumor-induced angiogenesis, and fibrin degradation products possess potent angiogenic properties.6,17 As a degradation product of cross-linked fibrin, D-dimer is a global marker of the activation of the coagulation and fibrinolytic systems. Our study showed that high D-dimer levels at incident VTE diagnosis were associated with a 3.3-fold higher risk of developing cancer.

Increased D-dimer levels are associated with mortality independent of VTE,18 and studies have found that D-dimer is a predictor of progression and poor survival in various cancers.9,19,20 We found that subjects in the highest D-dimer tertile had more advanced cancers at the time of diagnosis, with 80% having some degree of cancer spread of which 75% had disseminated metastases. We also found that high D-dimer levels in subjects with cancer were associated with a higher risk of one year mortality. Previous studies have shown that the relative risk and cumulative incidence of VTE is overestimated in cancer patients due to a high mortality rate in these patients.14 In the present study, however, the risk estimates were essentially unchanged when competing risk of death was taken into account. This is likely explained by the short duration of follow-up, and that both high D-dimer levels and cancer are associated with death.

The limitations of our study include the lack of statistical power to evaluate the risk of cancer by subgroups of provoked and unprovoked VTE. Moreover, two different assays were used to measure D-dimer. However, the majority of VTE events (390/422) occurred during the period that the STA®-Liatest® D-Di FM assay was used (from 1998–2012), and our risk estimates remained essentially unchanged in a sensitivity analysis restricted to these patients (data not shown).

In conclusion, D-dimer >5000 ng/ml at incident VTE is associated with a higher risk of subsequent cancer within one and two years. High D-dimer levels are also associated with more aggressive tumor biology and poor prognosis in these patients. As D-dimer is routinely measured in the assessment of suspected VTE, it may be a useful surrogate marker for the presence of an underlying malignancy. Our findings may suggest that high plasma D-dimer at incident VTE diagnosis should be taken into consideration when the decision to screen for underlying cancer is made.

Footnotes

  • Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

  • Copyright© Ferrata Storti Foundation

References

  1. 1.↵
    1. Trousseau A
    . CJt. Lectures on clinical medicine: Delivered at the Hotel-Dieu, Paris. The New Syndenham Society. 1872.
  2. 2.↵
    1. Prandoni P,
    2. Piccioli A
    . Venous thromboembolism and cancer: a two-way clinical association. Front Biosci. 1997;2:e12–20.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Baron JA,
    2. Gridley G,
    3. Weiderpass E,
    4. Nyren O,
    5. Linet M
    . Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077–1080.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Sorensen HT,
    2. Mellemkjaer L,
    3. Steffensen FH,
    4. Olsen JH,
    5. Nielsen GL
    . The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338(17): 1169–1173.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Trujillo-Santos J,
    2. Prandoni P,
    3. Rivron-Guillot K,
    4. et al
    . Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost. 2008; 6(2): 251–255.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kasthuri RS,
    2. Taubman MB,
    3. Mackman N
    . Role of tissue factor in cancer. J Clin Oncol. 2009; 27(29): 4834–4838.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gale AJ,
    2. Gordon SG
    . Update on tumor cell procoagulant factors. Acta Haematol. 2001;106(1–2): 25–32.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Wells PS,
    2. Anderson DR,
    3. Rodger M,
    4. et al
    . Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–1235.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Ay C,
    2. Dunkler D,
    3. Pirker R,
    4. et al
    . High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97(8):1158–1164.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Jacobsen BK,
    2. Eggen AE,
    3. Mathiesen EB,
    4. Wilsgaard T,
    5. Njølstad I
    . Cohort profile: The Tromsø Study. Int J Epidemiol. 2011;41(4):961–967.
    OpenUrlPubMed
  11. 11.↵
    1. Braekkan SK,
    2. Borch KH,
    3. Mathiesen EB,
    4. Njolstad I,
    5. Wilsgaard T,
    6. Hansen JB
    . Body height and risk of venous thromboembolism: The Tromso Study. Am J Epidemiol 2010; 171(10): 1109–1115.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Fine JP,
    2. Gray RJ
    . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
    OpenUrlCrossRefWeb of Science
  13. 13.↵
    1. Søgaard KK,
    2. Schmidt M,
    3. Pedersen L,
    4. Horváth–Puhó E,
    5. Sørensen HT
    . 30-year mortality after venous thromboembolism. Circulation. 2014; 130(10):829–836.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ay C,
    2. Posch F,
    3. Kaider A,
    4. Zielinski C,
    5. Pabinger I
    . Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost. 2015;13(3):390–397.
    OpenUrl
  15. 15.↵
    1. Schutgens RE,
    2. Beckers MM,
    3. Haas FJ,
    4. Biesma DH
    . The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica. 2005;90(2):214–219.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Han D,
    2. B OH,
    3. Lee JH,
    4. et al
    . Impact of D-Dimer for prediction of incident occult cancer in patients with unprovoked venous thromboembolism. PLoS One. 2016;11(4):e0153514.
    OpenUrl
  17. 17.↵
    1. Thompson WD,
    2. Smith EB,
    3. Stirk CM,
    4. Marshall FI,
    5. Stout AJ,
    6. Kocchar A
    . Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol. 1992;168(1):47–53.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Posch F,
    2. Riedl J,
    3. Reitter EM,
    4. et al
    . Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model. Thromb Haemost. 2016;115(4):817–826.
    OpenUrl
  19. 19.↵
    1. Stender MT,
    2. Larsen TB,
    3. Sorensen HT,
    4. Thorlacius-Ussing O
    . Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost. 2012;10(10): 2027–2031.
    OpenUrlPubMed
  20. 20.↵
    1. Inal T,
    2. Anar C,
    3. Polat G,
    4. Unsal I,
    5. Halilcolar H
    . The prognostic value of D-dimer in lung cancer. Clin Respir J. 2015;9(3):305–313.
    OpenUrl
PreviousNext
Back to top

Vol 101 Issue 12

Haematologica: 101 (12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Keywords

disorders of coagulation and fibrinolysisl
Venous Thrombosis
D-dimer
cancer
Email

Thank you for your interest in spreading the word about Haematologica.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
D-dimer measured at first venous thromboembolism is associated with future risk of cancer
(Your Name) has forwarded a page to you from Haematologica
(Your Name) thought you would like to see this page from the Haematologica web site.
Print
Citation Tools
D-dimer measured at first venous thromboembolism is associated with future risk of cancer
Olga V. Gran, Sigrid K. Brækkan, Benedikte Paulsen, Hanne Skille, John-Bjarne Hansen
Haematologica Dec 2016, 101 (12) e473-e475; DOI: 10.3324/haematol.2016.151712

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Olga V. Gran, Sigrid K. Brækkan, Benedikte Paulsen, Hanne Skille, John-Bjarne Hansen
Haematologica Dec 2016, 101 (12) e473-e475; DOI: 10.3324/haematol.2016.151712
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Request Permissions
  • Tweet Widget
  • Facebook Like
  • Alert me when this article is cited
  • Alert me if a correction is posted

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

More in this TOC Section

  • Kikuchi-Fujimoto disease and breast implants: is there a relationship?
  • Measurement of platelet count with different anticoagulants in thrombocytopenic patients and healthy subjects: accuracy and stability over time
  • ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients
Show more Online Only Articles

Related Articles

Cited By...

What about you?
Tell us your interests and get all the new contents of Haematologica in advance

 

 

Navigate

  • Home
  • Current issue
  • Ahead of print
  • Archive
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About us
    • About Haematologica
    • Editorial Board
    • Our policies

For Authors

  • Author guidelines
  • Submit Manuscript
  • Track Manuscript

For Reviewers

  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
  • 2014 reviewers

For Advertisers

  • Information For Advertising

Education

  • Review Articles
  • Guideline Articles

More

  • Rights & Permissions
  • Advertising
  • Alerts
  • Feedback
  • Contact
  • App

Copyright © 2019 by the Ferrata Storti Foundation

ISSN 0390-6078 print

ISSN 1592-8721 online